Suzanne St Rose
Global RWE Lead TA MH and EH Boehringer Ingelheim
Dr. Suzanne St.Rose is the Global Real-World Evidence (RWE) Lead for the Therapeutic Area of Mental & Eye Health at Boehringer Ingelheim. Based in Ingelheim, Germany, she spearheads a RWE team and works cross-functional to integrate patient experience and real-world data to produce regulatory-grade and payer-relevant evidence. Dr. St.Rose is committed to building evidence architectures and governance frameworks that ensure consistency, transparency, and trust among internal stakeholders, regulators, and HTA bodies. Her strategic oversight in Eye Health & Emerging Areas spans the entire drug development lifecycle, from early stages to post-approval management. Dr. St.Rose brings extensive experience from senior leadership roles at global organizations such as Allergan, Takeda, and GlaxoSmithKline, where she made significant contributions in Medical Affairs, Pharmacoepidemiology, and Biostatistics across several therapeutic areas. In her current role, Dr. St.Rose focuses on navigating European datasets, creating robust integrated evidence plans, and leveraging AI to enhance RWE generation. Her work is crucial in optimizing vendor and real-world data selection to support decision-making and reimbursement strategies. Dr. St.Rose continues to transform regulatory challenges into competitive advantages for RWE leaders, driving innovation and improving patient outcomes
Seminars
- Identify the cultural and organisational impediments slowing down RWE integration, including confusion over ownership and traditional comfort zones
- Learn practical approaches for “rewiring” organisations so clinical, medical, and commercial functions view RWE as a shared opportunity
- Discover strategies for engaging stakeholders early, building trust in data use, and aligning evidence generation with broader business objectives
With the European Health Data Space (EHDS) regulation set to reshape access and secondary use of health data across Europe, pharma faces both opportunity and complexity. This workshop will provide a deep dive into how different geographies are preparing for EHDS, the practical lessons from the Nordic Valo Project pilot, and what these developments mean for RWE generation and regulatory engagement across Europe.
This workshop will gather experts to discuss:
- Breaking Down EHDS Timelines & Scope & Opportunities for Biopharma – What to realistically expect between now and 2028, and how will timelines for access, quality requirements, and cross-border use evolve? What are the main opportunities for Pharma and Mid-Biotechs with EHDS regulation?
- The Valo Project in the Nordics – How a pharma-led initiative is pioneering a “mini-EHDS” model, what’s been achieved so far, and practical learnings for broader European adoption
- Germany’s National Health Data Infrastructure – Early insights into one of Europe’s largest national databases, challenges in governance, and expected implications for pharma
- Balancing Country-Level Systems with EHDS Requirements – Opportunities and risks of overlapping national and EU-level frameworks
- Operational Readiness for Data Access – How to build internal processes, partnerships with hospitals, and technical infrastructure to shorten timelines from ideation to results once EHDS is live
- Data Quality in the EHDS Era – What standards will EHDS enforce, and how can pharma prepare systematic frameworks to ensure data is research-grade from the start?
